S&P 500 Futures
(-0.13%) 5 301.50 points
Dow J Futures
(-0.04%) 40 127 points
Nasdaq Futures
(-0.21%) 18 465 points
Oil
(0.43%) $81.70
Gas
(-1.51%) $1.692
Gold
(0.17%) $2 216.40
Silver
(-0.89%) $24.53
Platinum
(-0.31%) $906.85
USD/EUR
(0.44%) $0.928
USD/NOK
(0.72%) $10.85
USD/GBP
(0.35%) $0.794
USD/RUB
(-0.14%) $92.31

Realtime updates for Nurix Therapeutics, Inc. [NRIX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
100.00%
return 13.59%
SELL
66.67%
return 6.00%
Last Updated27 Mar 2024 @ 16:00

11.67% $ 14.54

BUY 61354 min ago

@ $9.02

Issued: 14 Feb 2024 @ 14:04


Return: 61.20%


Previous signal: Feb 14 - 09:30


Previous signal: Sell


Return: 0.89 %

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...

Stats
Today's Volume 1.33M
Average Volume 785 745
Market Cap 710.92M
EPS $0 ( 2024-02-15 )
Next earnings date ( $-0.800 ) 2024-04-11
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -5.49
ATR14 $0.0430 (0.30%)
Insider Trading
Date Person Action Amount type
2024-02-16 Van Houte Hans Sell 6 812 Common Stock
2024-02-13 Van Houte Hans Buy 150 000 Employee Stock Option (right to buy)
2024-02-13 Van Houte Hans Buy 45 000 Restricted Stock Units
2024-02-13 Ring Christine Buy 150 000 Employee Stock Option (right to buy)
2024-02-13 Ring Christine Buy 45 000 Restricted Stock Units
INSIDER POWER
91.85
Last 100 transactions
Buy: 2 499 418 | Sell: 108 263

Volume Correlation

Long: 0.25 (neutral)
Short: 0.97 (very strong)
Signal:(76.201) Expect same movement, but be aware

Nurix Therapeutics, Inc. Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nurix Therapeutics, Inc. Correlation - Currency/Commodity

The country flag 0.02
( neutral )
The country flag -0.29
( neutral )
The country flag 0.00
( neutral )
The country flag 0.20
( neutral )
The country flag 0.33
( neutral )
The country flag 0.87
( strong )

Nurix Therapeutics, Inc. Financials

Annual 2023
Revenue: $76.99M
Gross Profit: $63.33M (82.26 %)
EPS: $-2.65
Q4 2023
Revenue: $15.16M
Gross Profit: $11.40M (75.22 %)
EPS: $-0.770
Q3 2023
Revenue: $18.47M
Gross Profit: $15.08M (81.68 %)
EPS: $-0.680
Q2 2023
Revenue: $30.68M
Gross Profit: $27.34M (89.13 %)
EPS: $-0.400

Financial Reports:

No articles found.

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators